Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 25;20(5):1389-1392.
doi: 10.31557/APJCP.2019.20.5.1389.

Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy

Takashi Nagai  1 , Takehiko Okamura  1 , Yutaro Tanaka  1   2 , Yoshinobu Moritoki  1 , Daichi Kobayashi  1 , Takahiro Kobayashi  1 , Hidetoshi Akita  1 , Takahiro Yasui  2
Affiliations

Evaluation of the Dwell-Time and Dose Difference in Intravesical Bacillus Calmette-Guèrin Therapy

Takashi Nagai et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Bacillus Calmette-Guèrin (BCG) intravesical therapy is currently established using a low dose because of the high incidence of side-effects. Moreover, shortening the dwell time of BCG is conducted in some facilities owing to the complications associated with a long dwell time after injection. The method of BCG administration varies in each facility and even with each doctor. We evaluated whether the dwell-time and dose differences in patients who underwent intravesical BCG therapy is related to completion rates, adverse effects, and nonrecurrence rates. Methods: From November 2006 to April 2016, a total of 173 patients who received intravesical BCG therapy after transurethral resection of bladder tumor or transurethral biopsy were evaluated retrospectively. We allocated them into 4 groups based on the dose (40 or 80 mg BCG) and the dwell time (1 or 2 hours). Completion rate, side effects, and nonrecurrence rates were evaluated. Results: No significant improvement in the completion rate or reduction in side-effects was observed in any of the regimens. Although nonrecurrence rates for the 1-hour dwell time tended to be lower than the 2-hour dwell time, the difference was not significant. Conclusion: Our study suggests that reducing the BCG dose or shortening the dwell time does not reduce adverse effects or affect the nonrecurrence rate.

Keywords: BCG; dwell-time difference; dose difference.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The Rates of Adverse Effects for Each Group. A1; 80mg, 1 hour, A2; 80mg, 2 hours, B1; 40mg, 1 hour, B2; 40mg, 2hours
Figure 2
Figure 2
The Nonrecurrence Rates in Each Group. A1; 80mg, 1 hour, A2; 80mg, 2 hours, B1; 40mg, 1 hour, B2; 40mg, 2hours
Figure 3
Figure 3
The Nonrecurrence Rates Based on Dose (A) or Dwell Time (B)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Andius P, Fehrling M, Holmäng S. Intravesical bacillus Calmette-Guèrin therapy:experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int. 2005;96:1290–3. - PubMed
    1. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer:AUA/SUO Guideline. J Urol. 2016;196:1021–9. - PubMed
    1. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf. 1998;19:45–55. - PubMed
    1. Lockyer CR, Sedgwick JE, Gillatt DA. Beware the BCG failures:a review of one institution's results. Eur Urol. 2002;42:542–6. - PubMed
    1. Martínez-Piñeiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89:671–80. - PubMed

MeSH terms